Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Autolus Therapeutics Plc (AUTL)
NASDAQ:AUTL
RESEARCH TOOLSreports
Autolus Therapeutics (AUTL) Stock Price & Analysis
502 Followers
AUTL Stock Chart & Stats
Day’s Range$4.79 - $5.25
52-Week Range― - ―
Previous Close$4.84
Volume1.21M
Average Volume (3M)N/A
Market Cap
$842.65M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 02, 2024EPS Estimate
-$0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$9.26Price Target Upside92.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Autolus Therapeutics News
PremiumCompany Announcements
Autolus Therapeutics Announces Board Leadership Changes
Bulls Say, Bears Say
Bulls Say
Financial StrengthAutolus is well capitalized, with robust financial resources following a strategic partnership with BioNTech, ensuring strong support for the launch of obe-cel and further pipeline development.
Manufacturing And Supply ChainAutolus has achieved a significant milestone by completing its first facility inspection and obtaining a Good Manufacturing Practice (GMP) certificate for the Nucleus site, enabling commercial supply of obe-cel in the US and EU/UK markets.
Regulatory MilestoneObe-Cel is on track with regulatory activities and a set Prescription Drug User Fee Act (PDUFA) date, signaling potential approval and commercialization.
Bears Say
EarningsReported net loss per share was greater than consensus, indicating financial performance below market expectations.
Mergers And AcquisitionsLimited near-term operational benefits, and note that the transaction may temper short-term investor expectations that AUTL could be acquired.
Strategic AgreementsGiven an obe-cel royalty payaway, and BNTX option on AUTO1/22 and AUTO6NG, we believe AUTL is now a less likely M&A candidate.
---
Ownership Overview
0.00%
Insiders
1.16% Mutual Funds
1.50% Other Institutional Investors
97.34% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AUTL FAQ
What was Autolus Therapeutics Plc’s price range in the past 12 months?
Currently, no data Available
What is Autolus Therapeutics Plc’s market cap?
Currently, no data Available
When is Autolus Therapeutics Plc’s upcoming earnings report date?
Autolus Therapeutics Plc’s upcoming earnings report date is May 02, 2024 which is in 13 days.
How were Autolus Therapeutics Plc’s earnings last quarter?
Autolus Therapeutics Plc released its earnings results on Mar 14, 2024. The company reported -$0.44 earnings per share for the quarter, missing the consensus estimate of -$0.253 by -$0.187.
Is Autolus Therapeutics Plc overvalued?
According to Wall Street analysts Autolus Therapeutics Plc’s price is currently Undervalued.
Does Autolus Therapeutics Plc pay dividends?
Autolus Therapeutics Plc does not currently pay dividends.
What is Autolus Therapeutics Plc’s EPS estimate?
Autolus Therapeutics Plc’s EPS estimate is -$0.1.
How many shares outstanding does Autolus Therapeutics Plc have?
Currently, no data Available
What happened to Autolus Therapeutics Plc’s price movement after its last earnings report?
Autolus Therapeutics Plc reported an EPS of -$0.44 in its last earnings report, missing expectations of -$0.253. Following the earnings report the stock price went up 4.015%.
Which hedge fund is a major shareholder of Autolus Therapeutics Plc?
Among the largest hedge funds holding Autolus Therapeutics Plc’s share is Blackstone Inc.. It holds Autolus Therapeutics Plc’s shares valued at 132M.
---
Autolus Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.26 (92.92% Upside)
$9.26 (92.92% Upside)
Blogger Sentiment
Bullish
AUTL Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.6%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
163.04%
12-Months-Change
Fundamentals
Return on Equity
-101.61%
Trailing 12-Months
Asset Growth
-23.43%
Trailing 12-Months
Company Description
Autolus Therapeutics Plc
Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.
---
AUTL Company Deck
---
AUTL Earnings Call
Q4 2024
0:00 / 0:00
---
AUTL Stock 12 Months Forecast
Average Price Target
$9.26
▲(92.92% Upside)
Technical Analysis
Best Analysts Covering AUTL
1 Year
1 Year Success Rate
4/7 ratings generated profit
1 Year Average Return
+59.04%
assigned a buy rating last month
Copying Yanan Zhu's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +59.04% per trade.
---